Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETRANHA: AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
NCT05367440Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Primary completion
- Apr 2031
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of saruparib in Metastatic Prostate Cancer (mPC) (4 arms), sponsored by AstraZeneca. Primary endpoints: Number of patients with Adverse Events and Serious Adverse Events up to 2.3 years and Number of patients with Dose Limiting Toxicities at 35 days. Started Jun 2022; status: active, not recruiting.
02
Drugs
saruparib
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT05367440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367440.